Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NEMO: Neural Mechanisms in Late-Life Depression
NCT03128021Phase 4Completed
- Start
- May 2017
- Primary completion
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of escitalopram and levomilnacipran in major depressive disorder (MDD) (4 arms). Primary endpoints: Change in Montgomery Asberg Depression Rating Scale Score at 12 weeks and Change in Functional Connectivity at 1 day. Started May 2017; status: completed.
02
Drugs
escitalopramlevomilnacipran
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT03128021.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03128021.